Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RK 4

Next Previous
Drug Profile

RK 4

Alternative Names: RK-4

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn
  • Class Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cerebral infarction

Most Recent Events

  • 02 Oct 2025 Neurodawn plans a phase II trial for Cerebral infarction in China(Intraosseous) in November 2025 (NCT07203521, CTR20253883)
  • 30 Sep 2025 Neurodawn plans a phase I/II trial for Cerebral infarction in China (Intraosseous) in September 2025 (NCT07166380, CTR20253634, ChiCTR2500110119)
  • 08 May 2025 Preclinical trials in Cerebral infarction in China (Intraosseous) prior to May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top